Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $440.0 million
Deal Type : Acquisition
Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.
Product Name : Lidocaine HCl- Generic
Product Type : Other Small Molecule
Upfront Cash : $330.0 million
January 31, 2020
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $440.0 million
Deal Type : Acquisition
Lead Product(s) : Phenazon,Lidocaine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $15.9 million
Deal Type : Acquisition
Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn
Details : Through the acquisition, Lupin will leverage Renascience key products, which includes Otigo (phenazone/lidocaine HCl) for pain due to acute otitis media.
Product Name : Otigo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2025
Lead Product(s) : Phenazon,Lidocaine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $15.9 million
Deal Type : Acquisition
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eugia Steriles Receives FDA Approval for New Injectables Facility
Details : Lidocaine is a local anesthetic that's used to numb areas of the body before medical procedures, treat pain, and treat certain heart conditions.
Product Name : Lidocaine HCl-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2024
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform
Details : ST-01 is a controlled release formulation of lidocaine, a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels preventing pain signals at the nerve endings. It is being developed for acute p...
Product Name : ST-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%
Details : Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.
Product Name : Lidocaine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%
Details : Amneal has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic n...
Product Name : Lidocaine HCl-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
